Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2016 - Research and Markets

Research and Markets
Posted on: 03 Oct 16

Research and Markets has announced the addition of the "Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2016" report to their offering.

Human Cytomegalovirus Envelope Glycoprotein B (gB) Human Cytomegalovirus envelope glycoprotein B plays an important role in host cell entry and cell to cell virus transmission. It is involved in the initial attachment via binding to heparan sulfate together with the gM/gN complex that binds heparin with higher affinity. It interacts with host integrin ITGB1, PDGFRA and EGFR that likely serve as post attachment entry receptors. It participates in the fusion of viral and cellular membranes leading to virus entry into the host cell.

Human Cytomegalovirus Envelope Glycoprotein B (gB) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The molecules developed by Companies in Phase III, Phase I, IND/CTA Filed and Preclinical stages are 1, 1, 1 and 3 respectively.

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2016, outlays comprehensive information on the targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

  1. Introduction
  2. Human Cytomegalovirus Envelope Glycoprotein B (gB) Overview
  3. Therapeutics Development
  4. Pipeline Products for Human Cytomegalovirus Envelope Glycoprotein B (gB) - Overview
  5. Pipeline Products for Human Cytomegalovirus Envelope Glycoprotein B (gB) - Comparative Analysis
  6. Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics under Development by Companies
  7. Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics under Investigation by Universities/Institutes
  8. Human Cytomegalovirus Envelope Glycoprotein B (gB) Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Human Cytomegalovirus Envelope Glycoprotein B (gB) - Products under Development by Companies
  13. Human Cytomegalovirus Envelope Glycoprotein B (gB) - Products under Investigation by Universities/Institutes
  14. Human Cytomegalovirus Envelope Glycoprotein B (gB) - Companies Involved in Therapeutics Development
  • Astellas Pharma Inc.
  • Trellis Bioscience, Inc.
  • Vakzine Projekt Management GmbH
  • VBI Vaccines Inc
  • Vical Incorporated

For more information about this report visit http://www.researchandmarkets.com/research/8jhwtk/human

View source version on businesswire.com: http://www.businesswire.com/news/home/20161003006272/en/

Business Wire
www.businesswire.com

Last updated on: 03/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.